Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinoma

Gynecologic Oncology

Volumn 116, Issue 1, 2010, Pages 61-65

  Matsuo, Koji ^a   Eno, Michele L ^c   Im, Dwight D ^d,e   Rosenshein, Neil B ^d,e   Sood, Anil K ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d MERCY MEDICAL CENTER   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Extreme drug resistance; In vitro drug resistance assay; Ovarian cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; PACLITAXEL; TOPOTECAN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PERITONEUM CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE; UTERINE TUBE CARCINOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DATABASES, FACTUAL; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; EPITHELIAL CELLS; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 70749122965     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.09.018     Document Type: Article

References (13)

1. Samson D.J., Seidenfeld J., Ziegler K., and Aronson N. Chemotherapy sensitivity and resistance assays: a systematic review. J. Clin. Oncol. 22 (2004) 3618-3630
2. Kern D.H., and Weisenthal L.M. Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. J. Natl. Cancer. Inst. 82 (1990) 582-588
3. Holloway R.W., Mehta R.S., Finkler N.J., Li K.T., McLaren C.E., Parker R.J., and Fruehauf J.P. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecol. Oncol. 87 (2002) 8-16
4. Matsuo K., Bond V.K., Eno M.L., Im D.D., and Rosenshein N.B. Low drug resistance to both platinum and taxane chemotherapy on an in-vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian, and peritoneal cancer. Int. J. Cancer (2009) Dec 1;125(11):2721-7.
5. Oncotech, EDR Assay®, http://www.exiqon.com/dxps/Documents/edr_4_pager.pdf (as of May 6, 2009).
6. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., Verweij J., Van Glabbeke M., van Oosterom A.T., Christian M.C., and Gwyther S.G. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92 (2000) 205-216
7. McAlpine J.N., Eisenkop S.M., and Spirtos N.M. Tumor heterogeneity in ovarian cancer as demonstrated by in vitro chemoresistance assays. Gynecol. Oncol. 110 (2008) 360-364
8. Matsuo K., Eno M.L., Im D.D., and Rosenshein N.B. Chemotherapy time interval and development of platinum and taxane resistance in ovarian, fallopian, and peritoneal carcinomas. Arch. Gynecol. Obstet. (2009) [electronic publication Ahead of print]
9. Kern D.H. Heterogeneity of drug resistance in human breast and ovarian cancers. Cancer J. Sci. Am. 4 (1998) 41-45
10. Tewari K.S., Mehta R.S., Burger R.A., Yu I.R., Kyshtoobayeva A.S., Monk B.J., Manetta A., Berman M.L., Disaia P.J., and Fruehauf J.P. Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma. Gynecol. Oncol. 98 (2005) 360-368
11. Loizzi V., Chan J.K., Osann K., Cappuccini F., DiSaia P.J., and Berman M.L. Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy. Am. J. Obstet. Gynecol. 189 (2003) 1301-1307
12. Eltabbakh G.H., Piver M.S., Hempling R.E., Recio F.O., Lele S.B., Marchetti D.L., Baker T.R., and Blumenson L.E. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer. Gynecol. Oncol. 70 (1998) 392-397
13. Mäenpää J.U., Heinonen E., Hinkka S.M., Karnani P., Klemi P.J., Korpijaakko T.A., Kuoppala T.A., Laine A.M., Lähde M.A., Nuoranne E.K., et al. The subrenal capsule assay in selecting chemotherapy for ovarian cancer: a prospective randomized trial. Gynecol. Oncol. 57 (1995) 294-298